MedTrace Logo

Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies

NCT04335383 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2025-11-20

No results posted yet for this study

Summary

Pseudomonas aeruginosa is a pathogenic bacteria for human, especially in hospital settings. It can sometimes be multi-resistant to many or even to all antibiotics usually used for its treatment.

The aim of the study is to isolate and produce therapeutic antibodies against the bacteria Pseudomonas aeruginosa in order to provide an alternative treatment to antibiotics in case of infection with an antibiotic-resistant strain of Pseudomonas aeruginosa.

Conditions

  • Pseudomonas Aeruginosa
  • Multi-antibiotic Resistance

Interventions

BIOLOGICAL

Isolation of anti-Pseudomonas antibodies from type B lymphocytes

Blood sampling. Isolation of mononuclear cells from human peripheral blood by density gradient centrifugation. Identification of functional anti-Pseudomonas antibodies by ELISA and cellular infection assays.

Sponsors & Collaborators

  • University Hospital, Grenoble

    lead OTHER

Principal Investigators

  • Yvan CASPAR, Dr · University Hospital, Grenoble

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-05
Primary Completion
2026-10-31
Completion
2026-10-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04335383 on ClinicalTrials.gov